Table 4.

Positive attributes associated with IV administration reported by patients with cancer

Attribute	Description of attribute	Study sample
Efficacy8	Perception that IV treatment is more effective than oral	Patients with a primary diagnosis of lymphoma, breast, colorectal, gynecologic, lung, or other cancer
Someone else can administer8	Preference for treatment that one does not have to worry about administering to oneself	Patients with a primary diagnosis of lymphoma, breast, colorectal, gynecologic, lung, or other cancer
Experience with IV18	Refers to greater acceptance of IV treatment after previously undergoing chemotherapy	Patients with stage 5 non-small cell lung cancer
Ability to treat illness19	Perception that IV treatment helped to keep one’s disease under control	Patients with cancer-associated venous thromboembolism, with the following primary cancer type: breast, ovarian, colorectal, bowel, cholangiocarcinoma, colon, lung, renal cell, and stomach
Treatment schedule8,17	Preference for treatment that can be administered in 1 day or for a shorter duration of time	Postmenopausal patients with early ER+/HER2− breast cancer and who had been previously treated with adjuvant chemotherapy;17 patients with a primary diagnosis of lymphoma, breast, colorectal, gynecologic, lung, or other cancer8
Interference with daily activities24	Perception that IV treatment interferes less with one’s daily life	Patients with colorectal cancer

Abbreviations: IV, intravenous; ER+, estrogen receptor-positive; HER2−, human epidermal growth factor receptor 2-negative.